摘要
JOSEPH Romanelli was extremely busy during the second China International Import Expo(CIIE)in Shanghai.The global senior vice president and China region president of the U.S.-based pharmaceutical company Merck&Co.,Inc.(also known as MSD)dealt with a flood of orders that came in for its new tumor immunotherapy drug PD-1 inhibitor.It has a significant therapeutic effect on tumors and attracted much interest from buyers in the medical field at the expo that took place from November 5 to 10.“China’s medical market has huge potential,and I am very optimistic about the Chinese market,”said Romanelli.
